Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes (Q42404578)
Jump to navigation
Jump to search
scientific article published on 26 July 2016
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes |
scientific article published on 26 July 2016 |
Statements
1 reference
Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes (English)
1 reference
Teruo Jojima
1 reference
Takanori Tomotsune
1 reference
Toshie Iijima
1 reference
Kazumi Akimoto
1 reference
Kunihiro Suzuki
1 reference
Yoshimasa Aso
1 reference
1 reference
1 reference
Identifiers
1 reference